Wired: How Politics, Industry Ties, and a 30-Day Comment Period Shape the 7-OH Ban

Why it matters

The DEA action on 7-OH is playing out against a backdrop of political alliances, industry lobbying, and competing consumer voices — factors that will shape how the 30-day public comment period unfolds and whether the temporary scheduling becomes permanent.

The big picture

Natural kratom has long been used in Southeast Asia and by millions of Americans, often for pain management and opioid withdrawal support. The last several years saw an explosion in unregulated concentrated and synthetic 7-OH products far more potent than the natural leaf. The DEA's proposed threshold-based scheduling draws a regulatory line between the two — but 7-OH advocates argue the ban lacks scientific basis and will push consumers toward more dangerous alternatives.

Key findings

• The scheduling would place 7-OH above a specified concentration threshold in Schedule I — the same category as heroin — for an initial two-year period
• President Trump endorsed natural kratom in May 2026, calling the administration was looking at getting it approved
• HHS Secretary RFK Jr. and DHS Secretary Mullin have documented ties to the kratom industry; Mullin has invested up to $1 million in Botanic Tonics, maker of Feel Free kratom drinks
• The American Kratom Association hailed the action, saying it ends debate over chemically manipulated 7-OH versus natural leaf kratom
• A 7-OH advocacy group (HART) says hundreds of thousands of consumers will submit comments describing how the compound helped them manage pain and reduce opioid use
• The DEA also announced parallel action against additional synthetic opioid analogs unrelated to kratom

What they say

"This DEA action should end the debate," said Mac Haddow, senior fellow on public policy for the American Kratom Association. "Chemically manipulated 7-OH opioids are not kratom. They are dangerous products that exploited the reputation of natural kratom leaf, misled consumers, and created a public health threat that responsible regulators can no longer ignore."

Bottom line

The 7-OH scheduling fight has become a proxy battle over the future of the kratom industry itself — pitting synthetic product makers against natural leaf advocates, with the public comment period as the next major inflection point.